Literature DB >> 25579528

Management of brain metastases from non-small cell lung cancer.

Meltem Baykara1, Gokhan Kurt, Suleyman Buyukberber, Umut Demirci, Necdet Ceviker, Efnan Algin, Ugur Coskun, Sukru Aykol, Hakan Emmez, Ahmet Ozet, Mustafa Benekli.   

Abstract

PURPOSE: The purpose of the following study is to evaluate the treatment modalities, clinical status and prognostic factors affecting survival rates in patients with newly diagnosed brain metastasis from non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: NSCLC patients with a new diagnosis of one to four brain metastasis evaluated retrospectively for the effects of treatment regimens on local failure-relapse-free survival (LRFS) and overall survival (OS). The relationship between age, gender, performance status, recursive partitioning analysis (RPA) classification, the primary tumor under control, number of metastatic tumors in the brain and total volume of brain metastasis and prognosis is analyzed.
RESULTS: Out of a total of 138 (121 male and 17 female) patients, nearly 44.2% received only gamma-knife (GK); 24.6% were received both GK and whole brain radiotherapy (WBRT), 2.9% had GK and surgery, 3.6% received GK, surgery and WBRT, 10.9% had surgery and WBRT and 12.3% received only WBRT for treatment. Median LRFS of surgery plus WBRT group was significantly higher when compared with WBRT group (P<0.0001). The OS was significantly longer for surgery plus WBRT group than the other treatment groups (P=0.037). When median survival of WBRT-only group compared with surgery plus WBRT, it was significantly higher (29.6 months vs. 16.7 months, P=0.006). Median OS of surgery plus WBRT group was significantly higher than GK plus WBRT group (29.6 months vs. 9.3 months, P=0.007).
CONCLUSION: WBRT is still the most effective treatment method following surgery in selected patients according to their age, performance status and spread of the primary disease with NSCLC had limited number brain metastasis. Adding WBRT treatment after surgery significantly improved OS and LRFS.

Entities:  

Mesh:

Year:  2014        PMID: 25579528     DOI: 10.4103/0973-1482.137939

Source DB:  PubMed          Journal:  J Cancer Res Ther        ISSN: 1998-4138            Impact factor:   1.805


  6 in total

Review 1.  Brain metastasis in lung cancer: Building a molecular and systems-level understanding to improve outcomes.

Authors:  Johnathan D Ebben; Ming You
Journal:  Int J Biochem Cell Biol       Date:  2016-07-27       Impact factor: 5.085

2.  Quality of life and efficacy of temozolomide combined with whole-brain radiotherapy in patients with brain metastases from non-small-cell lung cancer.

Authors:  Yajuan Lv; Jiandong Zhang; Zhen Liu; Ning Liang; Yuan Tian
Journal:  Mol Clin Oncol       Date:  2018-05-10

3.  CAVEOLIN-1 expression in brain metastasis from lung cancer predicts worse outcome and radioresistance, irrespective of tumor histotype.

Authors:  Eleonora Duregon; Rebecca Senetta; Alessandra Pittaro; Ludovica Verdun di Cantogno; Giulia Stella; Pierpaolo De Blasi; Michele Zorzetto; Cristina Mantovani; Mauro Papotti; Paola Cassoni
Journal:  Oncotarget       Date:  2015-10-06

4.  The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer.

Authors:  Hao Bai; Liwen Xiong; Baohui Han
Journal:  Onco Targets Ther       Date:  2017-04-27       Impact factor: 4.147

5.  Therapeutic Effect Of First-Line EGFR-TKIs Combined With Concurrent Cranial Radiotherapy On NSCLC Patients With EGFR Activating Mutation And Brain Metastasis: A Retrospective Study.

Authors:  Ning An; Haoyi Wang; Ji Li; Xiaoyang Zhai; Wang Jing; Wenxiao Jia; Li Kong; Hui Zhu; Jinming Yu
Journal:  Onco Targets Ther       Date:  2019-10-08       Impact factor: 4.147

6.  Effect of Whole-Brain and Intensity-Modulated Radiotherapy on Serum Levels of miR-21 and Prognosis for Lung Cancer Metastatic to the Brain.

Authors:  Zhensheng Zhu; Qiurong Li; Mingjuan Xu; Zhongliang Qi
Journal:  Med Sci Monit       Date:  2020-10-30
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.